DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
?? English Version
? Cue Biopharma (CUE)
Investment Research Report — Platform Play: Immuno-STAT T-Cell Modulators
Update: November 26, 2025
⚠️ GOING CONCERN WARNING
? STRATEGIC PIVOT TO AUTOIMMUNE
NASDAQ: CUE | Price: ~$0.61 | Market Cap: ~$47M | 52-Week Range: $0.45 – $5.12
Table of Contents
1. Executive Summary
Cue Biopharma is a clinical-stage biotech developing Immuno-STAT biologics — injectable drugs that selectively modulate disease-relevant T-cells without broad immunosuppression. The platform has applications in both oncology and autoimmune diseases.
In July 2024, the company announced a strategic pivot to prioritize autoimmune programs (CUE-401) while seeking partners for its oncology assets (CUE-101, CUE-102). This represents a fundamental shift from cancer-focused to autoimmune-focused biotech.
Investment Profile:
- NOT a near-term binary catalyst play like CAPR or typical PDUFA stocks
- Medium-term thesis: CUE-401 IND filing (mid-2026) + potential oncology partnering deals
- Near-term cash events: ImmunoScape $10M payment (Q4 2025)
- High risk: Going concern warning, limited cash runway, early-stage pipeline
2. Pipeline Overview
? CUE-101 (Oncology — Lead Clinical Asset)
Phase 1 Seeking PartnerTarget: HPV16-driven cancers (HNSCC, cervical, anal, oropharyngeal)
Mechanism: IL-2-based Immuno-STAT that activates HPV16-specific T-cells
Status: Mono and combo (+ pembrolizumab) Phase 1 ongoing; mature survival data accumulating
Key Data: 50% ORR in combo, 12-month OS 88%, median OS 32.7 months
? CUE-102 (Oncology)
Phase 1 Seeking PartnerTarget: WT1-expressing solid tumors (ovarian, pancreatic, AML)
Status: Early Phase 1, dose escalation
⭐ CUE-401 (Autoimmune — LEAD PROGRAM)
Preclinical / IND-EnablingTarget: Treg “master switch” — selective Treg activation without broad immunosuppression
Indication: Atopic dermatitis (first indication); potential in multiple autoimmune diseases
Status: IND-enabling studies; Pre-IND feedback positive from FDA
Timeline: IND filing expected mid-2026
? CUE-501 (Partnered with Boehringer Ingelheim)
PartneredPartner: Boehringer Ingelheim
Economics: $12M upfront + up to $345M milestones + royalties
Status: Boehringer responsible for development
3. Recent Strategic Deals
? ImmunoScape Collaboration (November 2025)
| Type | Strategic Collaboration & License |
| Focus | “Seed-and-Boost” cell therapy for solid tumors combining CUE-100 with ImmunoScape TCRs |
| Upfront | $15M ($10M in Q4 2025, $5M in Nov 2026) |
| Equity | 40% stake in ImmunoScape |
| Royalties | High-single-digit on net sales |
| IND Target | 2027 |
? Boehringer Ingelheim Partnership (CUE-501)
| Upfront Received | $12M |
| Total Milestones | Up to $345M |
| Royalties | Tiered royalties on net sales |
4. Clinical Data Highlights
CUE-101 + Pembrolizumab (1L HPV16+ HNSCC)
| Metric | Result | Context |
|---|---|---|
| Overall Response Rate (ORR) | 50% | Includes new complete responses |
| 12-Month Overall Survival | 88% | Strong durability signal |
| Median Overall Survival | 32.7 months | Compares favorably to historical data |
| Safety Profile | No significant IL-2 toxicities | Key differentiator vs. high-dose IL-2 |
Clinical Significance: The mature survival data positions CUE-101 as an attractive partnering asset. The company is actively seeking a partner to fund Phase 2/3 development while focusing internal resources on CUE-401.
5. Financial Analysis (SEC-Verified)
5.1 Income Statement (Q3 2025)
| Item ($M) | Q3 2025 | Q3 2024 | Change |
|---|---|---|---|
| Collaboration Revenue | $2.1 | $3.3 | -36% |
| R&D Expenses | $4.8 | $9.4 | -49% |
| G&A Expenses | $4.9 | $2.9 | +69% |
| Net Loss | ($7.45) | ($8.66) | -14% |
| EPS (Diluted) | ($0.07) | ($0.17) | Improved |
5.2 Balance Sheet (September 30, 2025)
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash & Equivalents | $11.7M | $22.5M |
| Total Assets | $18.2M | $28.4M |
| Total Liabilities | $8.1M | $9.2M |
| Stockholders’ Equity | $10.1M | $19.2M |
⚠️ Going Concern Warning: The Q3 2025 10-Q includes a going concern statement indicating insufficient capital to continue operations beyond the next twelve months without additional financing. However, the $10M ImmunoScape payment (Q4 2025) extends runway into H1 2026.
5.3 Pro-Forma Cash Position (Post-Deals)
| Item | Amount | Timing |
|---|---|---|
| Cash (Sep 30, 2025) | $11.7M | Reported |
| ImmunoScape Upfront #1 | +$10.0M | Q4 2025 |
| ImmunoScape Upfront #2 | +$5.0M | Nov 2026 |
| Estimated Cash Runway | Into Q2-Q3 2026 (before additional financing) | |
6. Upcoming Catalysts
? Q4 2025 — ImmunoScape Cash-In
$10M upfront payment from ImmunoScape collaboration expected to close in Q4 2025. Extends cash runway and validates oncology platform value.
? Q4 2025 / Q1 2026 — Corporate Update
New corporate presentation filed November 24, 2025 with CUE-401 as primary focus. Potential investor day or KOL event to detail autoimmune strategy and first indication (atopic dermatitis).
? H1 2026 — CUE-101 Survival Data Updates
Additional mature survival cuts from Phase 1 CUE-101 + pembro trial expected at oncology conferences (ASCO, ESMO IO). Could trigger partnering discussions.
⭐ Mid-2026 — CUE-401 IND Filing (KEY CATALYST)
Primary de-risking event. IND submission for CUE-401 in atopic dermatitis would transform the company from “platform story” to “clinical autoimmune biotech.” FDA Pre-IND feedback was positive.
? 2026 — Potential CUE-101/102 Partnering
With maturing survival data and validated mechanism, the oncology assets become increasingly attractive for licensing/partnering with larger pharma.
7. Key Risks
7.1 Financial/Dilution Risk
- Going concern warning in latest 10-Q — insufficient capital without additional financing
- Cash of $11.7M + $10M ImmunoScape = ~$21.7M, but burn rate ~$7-8M/quarter implies runway only into mid-2026
- Dilution likely before or around CUE-401 IND filing
7.2 Pipeline/Clinical Risk
- CUE-401 is still preclinical — IND filing ~6 months away, first clinical data 12-18 months out
- Oncology programs (CUE-101/102) deprioritized — success depends on finding a partner
- Platform technology unproven in autoimmune diseases (only oncology data so far)
7.3 Strategic Risk
- Pivot risk: Company pivoted from oncology to autoimmune in mid-2024 — execution on new strategy unproven
- Leadership change: New CEO (Usman Azam) as of September 2025 — transition period
- No near-term binary catalysts: Unlike CAPR, there’s no Phase 3 readout imminent
8. Valuation Scenarios
? Bull Case (18-24 months)
$3 – $5
CUE-401 IND filed successfully, first patients dosed, oncology partnering deal announced ($50M+ upfront). Market re-rates as “autoimmune platform with clinical validation.”
? Base Case
$0.80 – $1.50
CUE-401 advances on schedule, no major partnering deal, dilutive financing in H1 2026. Stock gradually re-rates as IND approaches.
? Bear Case
$0.20 – $0.40
CUE-401 development delays, no partnering interest for oncology, heavily dilutive financing or reverse split. Going concern becomes more acute.
Positioning Note: CUE is NOT a short-term catalyst play. Position sizing should reflect the 12-18 month timeline to CUE-401 clinical data and the significant financing/dilution risk. Suitable only for investors with high risk tolerance and multi-quarter holding period.
9. Sources & SEC Links
SEC Filings
Press Releases (GlobeNewswire)
Company Resources
?? Versione Italiana
? Cue Biopharma (CUE)
Investment Research Report — Platform Play: Modulatori T-Cell Immuno-STAT
Aggiornamento: 26 Novembre 2025
⚠️ GOING CONCERN WARNING
? PIVOT STRATEGICO SU AUTOIMMUNI
NASDAQ: CUE | Prezzo: ~$0.61 | Market Cap: ~$47M | Range 52-Settimane: $0.45 – $5.12
1. Executive Summary
Cue Biopharma è una biotech clinica che sviluppa biologici Immuno-STAT — farmaci iniettabili che modulano selettivamente i T-cell disease-relevant senza immunosoppressione sistemica. La piattaforma ha applicazioni sia in oncologia che nelle malattie autoimmuni.
A luglio 2024, la società ha annunciato un pivot strategico per prioritizzare i programmi autoimmuni (CUE-401) cercando partner per gli asset oncologici (CUE-101, CUE-102). Questo rappresenta un cambio fondamentale da biotech cancer-focused a autoimmune-focused.
Profilo di Investimento:
- NON è un play su catalyst binario a breve termine come CAPR o tipici titoli con PDUFA
- Tesi di medio termine: IND filing CUE-401 (metà 2026) + potenziali deal di partnering oncologia
- Eventi cash a breve: Pagamento ImmunoScape $10M (Q4 2025)
- Alto rischio: Going concern warning, runway limitata, pipeline early-stage
2. Overview Pipeline
? CUE-101 (Oncologia — Lead Asset Clinico)
Phase 1 In Cerca di PartnerTarget: Tumori HPV16-driven (HNSCC, cervicale, anale, orofaringeo)
Status: Phase 1 mono e combo (+ pembrolizumab) in corso; dati di sopravvivenza maturi
Dati Chiave: 50% ORR in combo, 12-month OS 88%, median OS 32.7 mesi
⭐ CUE-401 (Autoimmuni — PROGRAMMA LEAD)
Preclinico / IND-EnablingTarget: “Master switch” Treg — attivazione selettiva Treg senza immunosoppressione sistemica
Indicazione: Dermatite atopica (prima indicazione); potenziale in multiple malattie autoimmuni
Timeline: IND filing atteso metà 2026
? CUE-501 (Partnership con Boehringer Ingelheim)
PartneredEconomics: $12M upfront + fino a $345M milestones + royalties
3. Deal Strategiche Recenti
? Collaborazione ImmunoScape (Novembre 2025)
| Focus | Cell therapy “Seed-and-Boost” per tumori solidi |
| Upfront | $15M ($10M in Q4 2025, $5M in Nov 2026) |
| Equity | 40% stake in ImmunoScape |
| Royalties | High-single-digit sulle vendite nette |
4. Analisi Finanziaria (SEC-Verificata)
4.1 Stato Patrimoniale (30 Settembre 2025)
| Voce | 30 Set 2025 | 31 Dic 2024 |
|---|---|---|
| Cash & Equivalents | $11.7M | $22.5M |
| Totale Attività | $18.2M | $28.4M |
| Totale Passività | $8.1M | $9.2M |
| Patrimonio Netto | $10.1M | $19.2M |
⚠️ Going Concern Warning: Il 10-Q Q3 2025 include un avvertimento sulla capacità di continuare le operazioni oltre i prossimi dodici mesi senza finanziamenti aggiuntivi. Tuttavia, il pagamento ImmunoScape da $10M (Q4 2025) estende la runway fino a H1 2026.
5. Catalyst Prossimi
? Q4 2025 — Cash-In ImmunoScape
Pagamento upfront $10M dalla collaborazione ImmunoScape atteso in Q4 2025. Estende la runway e valida il valore della piattaforma oncologia.
? H1 2026 — Aggiornamento Dati Sopravvivenza CUE-101
Ulteriori cut di sopravvivenza dal trial Phase 1 CUE-101 + pembro attesi a conferenze oncologia (ASCO, ESMO IO). Potrebbe triggerare discussioni di partnering.
⭐ Metà 2026 — IND Filing CUE-401 (CATALYST CHIAVE)
Evento primario di de-risking. La submission IND per CUE-401 in dermatite atopica trasformerebbe la società da “platform story” a “biotech autoimmune clinica.”
6. Rischi Principali
- Going concern warning nell’ultimo 10-Q — capitale insufficiente senza finanziamenti aggiuntivi
- Cash di $11.7M + $10M ImmunoScape = ~$21.7M, ma burn rate ~$7-8M/trimestre implica runway solo fino a metà 2026
- Diluizione probabile prima o intorno al filing IND CUE-401
- CUE-401 è ancora preclinico — primi dati clinici a 12-18 mesi
- Programmi oncologia (CUE-101/102) deprioritizzati — successo dipende dal trovare un partner
7. Scenari Valutativi
? Bull Case (18-24 mesi)
$3 – $5
IND CUE-401 filed con successo, primi pazienti dosati, deal di partnering oncologia annunciato ($50M+ upfront). Il mercato re-rata come “piattaforma autoimmune con validazione clinica.”
? Base Case
$0.80 – $1.50
CUE-401 avanza nei tempi, nessun deal di partnering importante, finanziamento diluitivo in H1 2026. Il titolo gradualmente si re-rata con l’avvicinarsi dell’IND.
? Bear Case
$0.20 – $0.40
Ritardi nello sviluppo CUE-401, nessun interesse di partnering per oncologia, finanziamento pesantemente diluitivo o reverse split. Going concern diventa più acuto.
Nota di Posizionamento: CUE NON è un play su catalyst a breve termine. Il sizing della posizione dovrebbe riflettere la timeline di 12-18 mesi ai dati clinici CUE-401 e il significativo rischio di finanziamento/diluizione. Adatto solo a investitori con alta tolleranza al rischio e orizzonte di holding multi-trimestrale.
8. Fonti e Link SEC
SEC Filing
Comunicati Stampa
Risorse Aziendali
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
